Analytical Data
-
Gene name
POLD1
- Application
-
Alternative Names
Polymerase (DNA directed) delta 1 catalytic subunit; CDC2; CDC2 homolog; CRCS10; DNA directed DNA polymerase delta 1; DNA directed polymerase delta 1; DNA pol delta 1; DNA polymerase delta catalytic subunit; DNA polymerase subunit delta p125; DPOD1_HUMAN; MDPL; POLD; POLD 1; POLD1; Polymerase (DNA directed) delta 1 catalytic subunit 125kDa; Polymerase (DNA) delta 1 catalytic subunit; Polymerase DNA directed delta 1 catalytic subunit 125kD; polymerase. DNA. delta
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P28340
-
Expression Region
1-1107 aa
-
AA Sequence
MDGKRRPGPGPGVPPKRARGGLWDDDDAPRPSQFEEDLALMEEMEAEHRLQEQEEEELQSVLEGVADGQVPPSAIDPRWLRPTPPALDPQTEPLIFQQLEIDHYVGPAQPVPGGPPPSHGSVPVLRAFGVTDEGFSVCCHIHGFAPYFYTPAPPGFGPEHMGDLQRELNLAISRDSRGGRELTGPAVLAVELCSRESMFGYHGHGPSPFLRITVALPRLVAPARRLLEQGIRVAGLGTPSFAPYEANVDFEIRFMVDTDIVGCNWLELPAGKYALRLKEKATQCQLEADVLWSDVVSHPPEGPWQRIAPLRVLSFDIECAGRKGIFPEPERDPVIQICSLGLRWGEPEPFLRLALTLRPCAPILGAKVQSYEKEEDLLQAWSTFIRIMDPDVITGYNIQNFDLPYLISRAQTLKVQTFPFLGRVAGLCSNIRDSSFQSKQTGRRDTKVVSMVGRVQMDMLQVLLREYKLRSYTLNAVSFHFLGEQKEDVQHSIITDLQNGNDQTRRRLAVYCLKDAYLPLRLLERLMVLVNAVEMARVTGVPLSYLLSRGQQVKVVSQLLRQAMHEGLLMPVVKSEGGEDYTGATVIEPLKGYYDVPIATLDFSSLYPSIMMAHNLCYTTLLRPGTAQKLGLTEDQFIRTPTGDEFVKTSVRKGLLPQILENLLSARKRAKAELAKETDPLRRQVLDGRQLALKVSANSVYGFTGAQVGKLPCLEISQSVTGFGRQMIEKTKQLVESKYTVENGYSTSAKVVYGDTDSVMCRFGVSSVAEAMALGREAADWVSGHFPSPIRLEFEKVYFPYLLISKKRYAGLLFSSRPDAHDRMDCKGLEAVRRDNCPLVANLVTASLRRLLIDRDPEGAVAHAQDVISDLLCNRIDISQLVITKELTRAASDYAGKQAHVELAERMRKRDPGSAPSLGDRVPYVIISAAKGVAAYMKSEDPLFVLEHSLPIDTQYYLEQQLAKPLLRIFEPILGEGRAEAVLLRGDHTRCKTVLTGKVGGLLAFAKRRNCCIGCRTVLSHQGAVCEFCQPRESELYQKEVSHLNALEERFSRLWTQCQRCQGSLHEDVICTSRDCPIFYMRKKVRKDLEDQEQLLRRFGPPGPEAW
-
Molecular Weight
150 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
POLD1, or DNA polymerase delta 1, plays a pivotal role in DNA replication and repair, significantly influencing genomic stability. Mutations in the POLD1 gene are associated with a range of disorders, including colorectal cancer and other hereditary syndromes. Understanding the structure and function of POLD1 is essential for elucidating the mechanisms of these pathologies. The study of recombinant POLD1 protein offers insights into its enzymatic activity, fidelity, and interaction with other proteins involved in DNA metabolism. Through the generation of recombinant POLD1 in various expression systems, such as bacterial or eukaryotic cells, researchers can produce sufficient quantities of the enzyme for biochemical assays and structural analysis. This research aims to dissect the functional domains of POLD1, investigate its post-translational modifications, and explore how its activity may be altered by mutations. These studies not only enhance our comprehension of DNA replication processes but also pave the way for potential therapeutic interventions targeting POLD1-related diseases. The ultimate goal is to leverage this knowledge for developing diagnostic tools and treatment strategies that can address the implications of POLD1 dysfunction in human health.
